Gene linked to risk of late-onset Alzheimer's:
This article was originally published in Clinica
Executive Summary
An international team of researchers has found an association between the CST3 gene and late-onset Alzheimer's disease. The researchers, based in Germany, Italy, Switzerland and the US, studied 517 Alzheimer's patients and 390 control subjects. They found that individuals who were over the age of 75 and homozygous for the CST3 gene, which encodes the endogenous proteinase inhibitor, cystatin C, were nearly nine times as likely to develop Alzheimer's disease as heterozygous individuals. Reporting their findings in the November issue of Archives of Neurology, they conclude that CST3 is a susceptibility gene for late-onset Alzheimer's disease, especially in patients aged over 75.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.